As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
Two Assets Outlicensed
Executive Summary
The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.
You may also be interested in...
HI Bio Reaches For The Lead With Phase II Primary Membranous Nephropathy Data
While Roche is in Phase III with Gazyva, HI-Bio thinks its autoantibody-depleting mechanism may be the best approach in PMN.
Deal Watch: Organon Obtains Rights To Perjeta, Prolia/Xgeva Biosimilars From Shanghai Henlius
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D
The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.